Researchers reported that platinum–antibody conjugates can enhance tumor recognition by the immune system, aiming to address a central limitation of immune checkpoint inhibitors: only a subset of patients derive meaningful benefit. The work focuses on how platinum-based conjugation can influence immune engagement and potentially improve the visibility of tumors to effector pathways. The strategy fits within ongoing immuno-oncology efforts that try to move beyond checkpoint blockade alone by engineering agents to prime or amplify immune interactions within the tumor microenvironment. The study adds a new chemistry-enabled lever for therapies that depend on immune context, not only tumor genetics.